Key facts
- It has raised $2.8M; the latest was Early Stage VC ($2.8M) in Mar 2025.
- Notable investors include Changjiang Growth Capital Investment Company, Guangzhou Hi-tech Investment Group.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BayONE Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for BayONE Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BayONE Scientific
Developer of life science and biotech innovation platforms aims to support advanced healthcare and biomedical research. The company's offerings feature proprietary cell culture systems, biologics development pipelines, and integrated RD and production workflows, helping pharmaceutical developers, research institutions, and healthcare providers access reliable biological products and services, enabling scalable deployment of cutting-edge biotechnological solutions across therapeutic and diagnostic applications.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2020
- Employees
- 60
- Website
- bayonesci.com/
- Ownership
- Privately Held (backing)
BayONE Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BayONE Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BayONE Scientific in its N-PORT filings yet. We sweep new filings monthly.